Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Ovarian carcinoma cells with low levels of beta-F1-ATPase are sensitive to combined platinum and 2-deoxy-D-glucose treatment.

Hernlund E, Hjerpe E, Avall-Lundqvist E, Shoshan M.

Mol Cancer Ther. 2009 Jul;8(7):1916-23. doi: 10.1158/1535-7163.MCT-09-0179. Epub 2009 Jun 30.

2.

Energy metabolism of leukemia cells: glycolysis versus oxidative phosphorylation.

Suganuma K, Miwa H, Imai N, Shikami M, Gotou M, Goto M, Mizuno S, Takahashi M, Yamamoto H, Hiramatsu A, Wakabayashi M, Watarai M, Hanamura I, Imamura A, Mihara H, Nitta M.

Leuk Lymphoma. 2010 Nov;51(11):2112-9. doi: 10.3109/10428194.2010.512966. Epub 2010 Sep 22.

PMID:
20860495
3.

Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose.

Maher JC, Wangpaichitr M, Savaraj N, Kurtoglu M, Lampidis TJ.

Mol Cancer Ther. 2007 Feb;6(2):732-41.

4.

Potentiation of cisplatin and carboplatin cytotoxicity by amphotericin B in different human ovarian carcinoma and malignant peritoneal mesothelioma cells.

Poulain L, Sichel F, Crouet H, Bureau F, Gauduchon P, Gignoux M, Le Talaër JY.

Cancer Chemother Pharmacol. 1997;40(5):385-90.

PMID:
9272114
5.

Resveratrol induces SIRT1- and energy-stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment.

Björklund M, Roos J, Gogvadze V, Shoshan M.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1459-67. doi: 10.1007/s00280-011-1640-x. Epub 2011 Apr 11.

PMID:
21479886
6.

Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.

Sharp SY, Mistry P, Valenti MR, Bryant AP, Kelland LR.

Cancer Chemother Pharmacol. 1994;35(2):137-43.

PMID:
7987990
7.

Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines.

Harstrick A, Bokemeyer C, Scharnofkse M, Hapke G, Reile D, Schmoll HJ.

Cancer Chemother Pharmacol. 1993;33(1):43-7.

PMID:
8269588
8.

Targeting cisplatin-resistant human tumor cells with metabolic inhibitors.

Sullivan EJ, Kurtoglu M, Brenneman R, Liu H, Lampidis TJ.

Cancer Chemother Pharmacol. 2014 Feb;73(2):417-27. doi: 10.1007/s00280-013-2366-8. Epub 2013 Dec 19.

PMID:
24352250
9.

Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.

Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, Fruehauf JP.

Gynecol Oncol. 2002 Oct;87(1):8-16.

PMID:
12468336
10.

Hematoporphyrin derivatives potentiate the radiosensitizing effects of 2-deoxy-D-glucose in cancer cells.

Dwarakanath BS, Adhikari JS, Jain V.

Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1125-33.

PMID:
10192364
11.

Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment.

Bagnoli M, Balladore E, Luison E, Alberti P, Raspagliesi F, Marcomini B, Canevari S, Mezzanzanica D.

Mol Cancer Ther. 2007 Feb;6(2):762-72.

12.

"Metabolic reprogramming" in ovarian cancer cells resistant to cisplatin.

Montopoli M, Bellanda M, Lonardoni F, Ragazzi E, Dorigo P, Froldi G, Mammi S, Caparrotta L.

Curr Cancer Drug Targets. 2011 Feb;11(2):226-35.

PMID:
21158717
13.

Heterogeneity in 2-deoxy-D-glucose-induced modifications in energetics and radiation responses of human tumor cell lines.

Dwarkanath BS, Zolzer F, Chandana S, Bauch T, Adhikari JS, Muller WU, Streffer C, Jain V.

Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):1051-61.

PMID:
11429233
14.

Aphidicolin markedly increases the platinum sensitivity of cells from primary ovarian tumours.

Sargent JM, Elgie AW, Williamson CJ, Taylor CG.

Br J Cancer. 1996 Dec;74(11):1730-3.

15.

Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.

Groen HJ, Sleijfer S, Meijer C, Kampinga HH, Konings AW, De Vries EG, Mulder NH.

Br J Cancer. 1995 Dec;72(6):1406-11.

17.

Early reduction of glucose uptake after cisplatin treatment is a marker of cisplatin sensitivity in ovarian cancer.

Egawa-Takata T, Endo H, Fujita M, Ueda Y, Miyatake T, Okuyama H, Yoshino K, Kamiura S, Enomoto T, Kimura T, Inoue M.

Cancer Sci. 2010 Oct;101(10):2171-8. doi: 10.1111/j.1349-7006.2010.01670.x. Epub 2010 Jul 30.

18.

Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest.

Zheng H, Hu W, Yu D, Shen DY, Fu S, Kavanagh JJ, Wei IC, Yang DJ.

Pharm Res. 2008 Oct;25(10):2272-82. doi: 10.1007/s11095-008-9621-4. Epub 2008 May 29.

PMID:
18509599
19.

High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.

Kozubík A, Horváth V, Svihálková-Sindlerová L, Soucek K, Hofmanová J, Sova P, Kroutil A, Zák F, Mistr A, Turánek J.

Biochem Pharmacol. 2005 Feb 1;69(3):373-83. Epub 2004 Dec 23.

PMID:
15652229
20.

Analysis of cellular sensitization with cisplatin-induced apoptosis by glucose-starved stress in cisplatin-sensitive and -resistant A431 cell line.

Mese H, Sasaki A, Nakayama S, Yokoyama S, Sawada S, Ishikawa T, Matsumura T.

Anticancer Res. 2001 Mar-Apr;21(2A):1029-33.

PMID:
11396136
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk